PatientsVille.com Logo

Nuclear magnetic resonance imaging abdominal and Magnevist

PatientsVille

Nuclear Magnetic Resonance Imaging Abdominal Symptoms and Causes

Magnetic resonance imaging (MRI) uses a large magnet and radio waves to look at organs and structures inside your body. Health care professionals use MRI scans to diagnose a variety of conditions, from torn ligaments to tumors. MRIs are very useful for examining the brain and spinal cord.

During the scan, you lie on a table that slides inside a tunnel-shaped machine. Doing the scan can take a long time, and you must stay still. The scan is painless. The MRI machine makes a lot of noise. The technician may offer you earplugs.

Before you get a scan, tell your doctor if you

  • Are pregnant
  • Have pieces of metal in your body. You might have metal in your body if you have a shrapnel or bullet injury or if you are a welder.
  • Have metal or electronic devices in your body, such as a cardiac pacemaker or a metal artificial joint

Check out the latest treatments for nuclear magnetic resonance imaging abdominal

nuclear magnetic resonance imaging abdominal treatment research studies

Magnevist clinical trials, surveys and public health registries


Find Drug Side Effect reports



Magnevist Side Effects

Nephrogenic Systemic Fibrosis (920)
Urticaria (813)
Nausea (573)
Pruritus (551)
Dyspnoea (517)
Vomiting (511)
Erythema (507)
Anxiety (443)
Joint Range Of Motion Decreased (438)
Pain (425)
Oedema Peripheral (387)
Mobility Decreased (370)
Emotional Distress (361)
Fibrosis (341)
Arthralgia (330)
Deformity (265)
Joint Stiffness (253)
Injury (243)
Joint Contracture (240)
Gait Disturbance (232)
Sneezing (232)
Dry Skin (225)
Asthenia (223)
Anhedonia (222)
Pain In Extremity (207)
Burning Sensation (197)
Rash (192)
Musculoskeletal Stiffness (191)
Cough (187)
Hypoaesthesia (182)
Extremity Contracture (180)
Skin Induration (165)
Dizziness (162)
Muscular Weakness (160)
Skin Hypertrophy (156)
Throat Irritation (144)
Fatigue (144)
Skin Tightness (135)
Nephrogenic Fibrosing Dermopathy (131)
Chest Discomfort (131)
Feeling Hot (126)
Nasal Congestion (125)
Anaphylactic Reaction (114)
Throat Tightness (113)
Flushing (112)
Hyperhidrosis (102)
Convulsion (100)
Back Pain (99)
Chest Pain (98)
Skin Discolouration (98)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

<b><span style='font-weight: normal;'><b>After 6 weeks of oral lamisil I experienced</b>eczema, muscle weakness, asthma, bloody bowels, lower abdominal pain, dizziness, extreme f

I took one Aleve at 3:30 PM and by 6:30 PM I had extreme abdominal pain lasting several hours and now the next day I still am uncomfortable. I will never take Aleve again!!

I AM 35 YEARS AND ON AN PERIMONOPAUSE AND JUST STARTED ACTIVELLE A FEW WEEKS AGO .I THEN STARTED HAVING SEVERE ABDOMINAL PAINS LIKE MENSTUAL PAIN AND DON'T KNOW WHETHER TO STOP OR CONTINUE.

<b>After taking this drug I suffered abdominal pain with diarrhea after eating even small amounts, pain developed with the urge to get to a toilet at once. I had a full blood and liver test and a stool test and all was normal.&nbs

<b>Describe Your Ezetrol Experience Here:</b>Sleeplessness severe pain in muscles and joints nausea and abdominal pain headaches and pain behind eyes chronic fatigue and flat mood

More common<span style='padding-top: 5px; padding-right: 0px; padding-bottom: 5px; padding-left: 30px; color: #444444; display: block;'>- Abdominal pain<span style='padding-top: 5px; padding-right: 0px; padd

25 YR OLD TRAPSPATIENT w/abdominal pain x 10 days. Stopped taking 100mg dail Kineret 3 days ago, now w/fever 100/102. Went to ER 5 days ago, w/no sign of inflammation in labs. Still have severe abdominal pain.&nbsp

Bad taste in my mouth, very bloated and abdominal pain and reflux

25 three boys. I have loved it. Only problem is occasional abdominal pains. Tonight after intercourse i started spotting and i am concerned as i have had this devise for several months and have never experienced this. I found out later that many wome

32 days on ezertrol 10mg and have severe abdominal cramping and look 6months pregnant, don't know where to go from here, back to the Doctor!!!

Nuclear Magnetic Resonance Imaging Abdominal Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Liver Lesions in Contrast-Enhanced Magnetic Resonance Imaging (MRI)
Condition: Liver Neoplasms
Interventions: Drug: Gadoxetate;   Drug: Gadopentetate Dimeglumine
Outcome Measure: Specificity of Contrast Enhanced MRI Using Eovist Versus Combined Use of Eovist and Magnevist
2 Recruiting Crossover Comparison of MultiHance and Dotarem
Condition: Brain Disease
Interventions: Drug: Gadobenate;   Drug: Gadoterate
Outcome Measure: Scores on global diagnostic preference
3 Recruiting Imaging Multiple Sclerosis Lesions Using Magnevist and Gadavist
Condition: Multiple Sclerosis
Intervention:
Outcome Measures: Lesion detection and quantification in Multiple Sclerosis Patients;   MR cerebral blood flow Quantification
4 Not yet recruiting ASIS for Enbrel in Plaque Psoriasis
Condition: Plaque Psoriasis.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Enbrel subcutaneously at Week 12;   Drug: Efficacy of Enbrel subcutaneously at Week 24;   Drug: Efficacy of Enbrel subcutaneously at Week 36;   Drug: Efficacy of Enbrel subdermally at Week 12;   Drug: Efficacy of Enbrel subdermally at Week 24;   Drug: Efficacy of Enbrel subdermally at Week 36;   Drug: PASI 75 n(%) subcutaneously at Week 12;   Drug: PASI 75 n(%) subcutaneously at Week 24;   Drug: PASI 75 n(%) subcutaneously at Week 36;   Drug: PASI 75 n(%) subdermally at Week 12;   Drug: PASI 75 n(%) subdermally at Week 24;   Drug: PASI 75 n(%) subdermally at Week 36;   Drug: Adverse Reactions of Enbrel subcutaneously;   Drug: Adverse Reactions of Enbrel subdermally at Week 36
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Enbrel subcutaneously vs. subdermally in Plaque Psoriasis.
5 Recruiting 3-Tesla MRI Response to TACE in HCC (Liver Cancer)
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Localized Resectable Adult Primary Liver Cancer;   Localized Unresectable Adult Primary Liver Cancer;   Stage A Adult Primary Liver Cancer (BCLC);   Stage B Adult Primary Liver Cancer (BCLC)
Interventions: Device: 3 Tesla Magnetic Resonance Imaging;   Drug: Magnevist® (Intravenous (IV) administration of MRI contrast agent)
Outcome Measures: Correlation of changes in imaging biomarkers (Ktrans, ADC, MTR, and APTasym) as measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, respectively, with changes in tumor volume (mRECIST).;   Correlation of changes in Ktrans, ADC, MTR, and APTasym (measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, respectively) with time-to-progression (TTP).;   Correlation of changes in Ktrans, ADC, MTR, and APTasym (measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, respectively) with changes in the ratio of viable-to-necrotic tumor volume;   Correlation of Ktrans, ADC, MTR, and APTasym (measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, respectively) with pathological response within explanted tissue following orthotopic liver transplant (OLT);   Correlation of changes in Ktrans, ADC, MTR, and APTasym (measured by DCE-, DW-, MT-, and CEST-MRI at 3 Tesla, respectively) with overall survival (OS)
6 Recruiting PET/CT or PET/MRI in Measuring Tumors in Patients Undergoing Clinical Imaging or With Newly Diagnosed Breast Cancer
Conditions: Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Procedure: positron emission tomography/computed tomography;   Radiation: fludeoxyglucose F 18;   Device: PET/MRI;   Radiation: gadopentetate dimeglumine;   Other: questionnaire administration
Outcome Measures: Attenuation correction for PET/MRI, assessed using standard uptake values (SUVs) (Cohorts I & II);   Attenuation correction for PET/CT, assessed using SUVs (Cohorts I & II);   Specificity rates of fused FDG-PET/MRI (Cohort III);   Sensitivity of PET/CT and PET/MRI (Cohort III)
7 Not yet recruiting ASIS for Botox in Upper Limb Spasticity
Conditions: Upper Limb Spasticity Unilaterally in Adults With History of Stroke;   Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Botox intramuscularly at Week 6;   Drug: Efficacy of Botox intramuscularly at Week 12,;   Drug: Efficacy of Botox intramuscularly at Week 18;   Drug: Efficacy of Botox intramuscularly at Week 24;   Drug: Efficacy of Botox intramuscularly at Week 30;   Drug: Efficacy of Botox subdermally at Week 6;   Drug: Efficacy of Botox subdermally at Week 12;   Drug: Efficacy of Botox subdermally at Week 18;   Drug: Efficacy of Botox subdermally at Week 24;   Drug: Efficacy of Botox subdermally at Week 30;   Drug: Adverse Reactions of Botox intramuscularly;   Drug: Adverse Reactions of Botox subdermally
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Botox intramuscularly vs. subdermally in Upper Limb Spasticity.
8 Not yet recruiting ASIS for Botox in Cervical Dystonia
Conditions: Cervical Dystonia Adults ,;   Abnormal Head Position and Neck Pain for These 7 Muscle Groups: Splenius,Scalene,Sterno-cleido-mastoid,Levator Scapulae,Semispinalis,Trapezius,and Longissimus.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Botox intramuscularly at Week 6;   Drug: Efficacy of Botox intramuscularly at Week 12;   Drug: Efficacy of Botox intramuscularly at Week 18;   Drug: Efficacy of Botox intramuscularly at Week 24;   Drug: Efficacy of Botox intramuscularly at Week 30;   Drug: Efficacy of Botox subdermally at Week 6;   Drug: Efficacy of Botox subdermally at Week 12;   Drug: Efficacy of Botox subdermally at Week 18;   Drug: Efficacy of Botox subdermally at Week 24;   Drug: Efficacy of Botox subdermally at Week 30;   Drug: Adverse Reactions of Botox intramuscularly;   Drug: Adverse Reactions of Botox subdermally
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Botox intramuscularly vs. subdermally in Cervical Dystonia.
9 Not yet recruiting ASIS for Botox in Chronic Migraine
Condition: Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer.
Interventions: Drug: Gadolinium;   Drug: Efficacy of Botox intramuscularly at Week 6;   Drug: Efficacy of Botox intramuscularly at Week 12;   Drug: Efficacy of Botox intramuscularly at Week 18;   Drug: Efficacy of Botox intramuscularly at Week 24,;   Drug: Efficacy of Botox intramuscularly at Week 30;   Drug: Efficacy of Botox subdermally at Week 6;   Drug: Efficacy of Botox subdermally at Week 12;   Drug: Efficacy of Botox subdermally at Week 18;   Drug: Efficacy of Botox subdermally at Week 24;   Drug: Efficacy of Botox subdermally at Week 30;   Drug: Adverse Reactions of Botox intramuscularly;   Drug: Adverse Reactions of Botox subdermally
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected.;   Efficacy of Botox intramuscularly vs. subdermally in Chronic Migraine.
10 Not yet recruiting ASIS for GAMMAGARD in Primary Immunodeficiency
Condition: Primary Immunodeficiency
Interventions: Drug: Gadolinium For abdomen;   Drug: Gadolinium For lower back;   Drug: Efficacy of Gammagard subcutaneously at Week 12;   Drug: Efficacy of Gammagard subcutaneously at Week 24;   Drug: Efficacy of Gammagard subcutaneously at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 36;   Drug: Efficacy of Gammagard subdermally at Week 12;   Drug: Efficacy of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 12;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 24;   Drug: Adverse Reactions of Gammagard subcutaneously at Week 36;   Drug: Adverse Reactions of Gammagard subdermally at Week 12;   Drug: Adverse Reactions of Gammagard subdermally at Week 24;   Drug: Adverse Reactions of Gammagard subdermally at Week 36
Outcome Measures: Relative Prolongation Ability Score for Gadolinium subdermally injected;   Efficacy of GAMMAGARD subcutaneously vs. subdermally in Primary Immunodeficiency
11 Recruiting Identification of Adverse Plaque Characteristics by Coronary MR Angiography
Condition: Coronary Artery Disease
Intervention: Other: Coronary MR Angiography (CMRA)
Outcome Measure: Adverse plaque characteristics present on CMRA
12 Recruiting Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis
Conditions: Breast Cancer Diagnosis;   Positron Emission Tomography;   Magnetic Resonance Imaging
Interventions: Drug: 18F-FCH;   Drug: Magnevist
Outcome Measures: diagnostic accuracy of 18F-FCH PET for breast cancer diagnosis;   Monitoring of treatment response of breast cancer to chemotherapy using 18F-FCH PET;   diagnostic accuracy of breast MR spectroscopy for breast cancer diagnosis
13 Recruiting 3T MRI Biomarkers of Glioma Treatment Response
Conditions: Adult Anaplastic Astrocytoma;   Adult Anaplastic Ependymoma;   Adult Anaplastic Oligodendroglioma;   Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Device: 3-Tesla magnetic resonance imaging;   Device: CEST-MRI;   Device: DW-MRI;   Device: DCE-MRI;   Device: DSC-MRI;   Drug: IV administration of gadolinium-containing contrast agent
Outcome Measures: Best Response;   Progression Free Survival (PFS)
14 Not yet recruiting Look at Way the Heart Functions in People With Pulmonary Hypertension (PH) Who Have Near Normal Right Ventricle (RV) Function and People With Pulmonary Hypertension Who Have Impaired RV Function. Using Imaging Studies PET Scan and Cardiac MRI.
Conditions: Pulmonary Arterial Hypertension;   Chronic Thromboembolic Pulmonary Hypertension
Interventions: Drug: 11C-acetate;   Drug: [18F]Fluoro-2-deoxy-2-D-glucose;   Drug: MultiHance
Outcome Measures: Myocardial oxygen consumption, FDG uptake, and myocardial perfusion;   Myocardial oxygen consumption and FDG uptake, and myocardial perfusion;   Changes in myocardial structure and function
15 Unknown  Molecular Imaging With Erlotinib and Bevacizumab
Condition: Non-Small-Cell Lung Carcinoma
Interventions: Drug: Erlotinib, Bevacizumab;   Drug: Fluoro-D-glucose;   Drug: Fluoro-L-thymidine;   Drug: Gadolinium-DPTA
Outcome Measures: To evaluate the accuracy of imaging findings in FDG-/FLT-PET and DCE-MRI after one week of treatment for early prediction of RECIST-based non-progression and progression-free survival after 6 weeks of therapy;   Correlation of mutational profiling with imaging characteristics Prognostic accuracy of imaging Pharmacokinetic analysis Reliability of DCE-MRI Correlation of peripheral biomarkers with clinical outcome, mutational profiling, imaging characteristics
16 Recruiting An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-grade Glioma
Conditions: Brain Neoplasm;   Glioma
Intervention: Drug: IL13-PE38QQR
Outcome Measures: 1) Feasibility of perfusing specific sites within the CNS with IL13-PE38QQR, administered concurrently with gd-DTPA, 2) Safety and tolerability of escalating doses of IL13-PE38QQR via CED to pediatric patient with DIPGs and HGGs;   Determine effect of IL13-PE38QQR on MRI tumor measurements, symptom improvement or worsening, changes on clinical exam, radiographic changes, steroid dosing, QOL testing and survival of pediatric patients with DIPG and recurrent HGG
17 Recruiting Neurovascular Non Contrast-Enhanced MR Angiography at 3T
Condition: Neurovascular Diseases
Intervention:
Outcome Measures: A reading grid assessing the image quality;   An evaluation grid classifying the main pathological findings
18 Not yet recruiting Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients
Condition: Central Nervous System Neoplasms
Intervention:
Outcome Measures: Degree of contrast induced signal changes with dynamic imaging of brain tumors;   Calculate differences in cerebral blood volume, ktrans and flow in brain tumors
19 Recruiting Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
Condition: Recurrent Malignant Glioma
Intervention: Drug: OKN-007
Outcome Measures: Number of Adverse events per patient;   PK level in participants;   6 month progression-free survival
20 Unknown  Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients
Conditions: Glomerular Filtration Rate;   Chronic Allograft Nephropathy
Intervention: Drug: sirolimus
Outcome Measures: Glomerular filtration rate measured by Gd-DTPA;   Quantification the histological markers on renal allograft biopsy;   Patient survival, graft survival, and incidence of acute rejection